Abera Bioscience AB Company Description

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally.

The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria.

Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC, Covid-19, and Tuberculosis.

Abera Bioscience AB was incorporated in 2012 and is based in Uppsala, Sweden.

Abera Bioscience AB

Country	Sweden
Founded	2012
Industry	Biological Products, Except Diagnostic Substances
Employees	6
CEO	Maria Alriksson

Contact Details

Address: Dragarbrunnsgatan 45 Uppsala, 753 720 Sweden
Website	aberabio.com

Stock Details

Ticker Symbol	ABERA
Exchange	Nordic Growth Market
Fiscal Year	January - December
Reporting Currency	SEK
SIC Code	2836

Key Executives

Name	Position
Maria Alriksson	Chief Executive Officer